Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

This study has been completed.
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Cellceutix Corporation Identifier:
First received: August 2, 2012
Last updated: February 23, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)